Company: JUNS
Filing Date: 2025-03-28
Form Type: 10-K
Source: 0001641172-25-001261
Chunk: 1421

Company: JUPITER NEUROSCIENCES, INC.
Filing Date: 2025-03-28
Form: 10-K
Item: Item 6
Chunk 1421
---
 terms that are not favorable to us or our
stockholders. If we are unable to raise additional funds when needed, we may be required to delay, reduce, or terminate some or all of
our development programs and clinical trials. We may also be required to sell or license to other parties rights to develop or commercialize
our drug candidate that we would prefer to retain.

See
“Risk Factors” for additional risks associated with our capital requirements.

Cash
Flows for the Years Ended December 31, 2024 and 2023

The
following table shows a summary of our cash flows for the years ended December 31, 2024 and 2023.

    Fiscal Years Ended December 31, 

    2024  
    2023 
  
    Net cash used in operating activities 
    $(3,911,004) 
    $(480,953)
  
    Net cash used in investing activities 
     -  
     - 
  
    Net cash provided by financing activities 
    $7,652,036  
    $445,000 
  
    Net increase (decrease) in cash 
    $3,741,032  
    $(35,953)
  
    Cash - beginning of the period 
    $   
    $  
  
    Cash - end of the period 
    $3,769,510  
    $28,478 

Net
Cash Used in Operating Activities:

Net
cash used in operating activities during the year ended December 31, 2024 increased $3,430,051 from December 31, 2023 mainly
attributable to an increase of $2,300,000 in prepaid contracts due to stock issuances associated with Asian Business Development
service agreements, an increase of $118,796 in other current assets, a decrease of $2,187,051 in accrued compensation, a decrease of
$314,412 in accounts payable and accrued expenses, a decrease of $1,517,085 in changes associated with debt (amortization of debt
discounts, loss on extinguishment of debt, gain/loss on change in fair value of derivative liabilities, and increase in accrued
interest), an increase in amortization of prepaid contracts of $54,612, an increase of $642,329 in stock-based compensation,
partially offset a decrease of $2,334,064 in Net Loss.

Net
Cash Used in Investing Activities:

No
net cash was provided by or